Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOMOPHYLLIN-CRT vs THEOCLEAR L.A.-130
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Theophylline acts as a bronchodilator via nonselective phosphodiesterase inhibition, increasing intracellular c AMP levels. It also antagonizes adenosine receptors and may have anti-inflammatory effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label),Facilitation of weaning from mechanical ventilation in neonates (off-label)
Treatment of asthma (FDA-approved),Treatment of chronic obstructive pulmonary disease (COPD) (off-label)
Theophylline 400 mg orally once daily (24-hour extended-release). Titrate based on serum theophylline levels; target trough 5-15 mcg/m L.
130 mg orally every 12 hours; extended-release tablet.
Terminal elimination half-life: 8-10 hours in adults (non-smokers); prolonged to 12-16 hours in elderly or hepatic impairment; reduced to 4-6 hours in smokers (CYP1A2 induction).
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
No specific dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 25% and monitor levels. For GFR <10 m L/min: reduce dose by 50% and monitor closely.
No specific adjustment required; monitor serum concentrations and adjust dose based on clinical response and trough levels.
Theophylline has a narrow therapeutic index; toxicity can occur at doses only slightly above therapeutic levels. Serious and potentially fatal adverse events, including seizures and cardiac arrhythmias, can occur, especially in patients with preexisting conditions or those receiving concurrent medications that affect theophylline clearance.
Theophylline (active ingredient in SOMOPHYLLIN-CRT) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxicity at high doses but no major malformations. Second and third trimesters: No established teratogenicity; may cause neonatal toxicity (irritability, jitteriness, vomiting) if maternal levels are high near term. Use only if benefit outweighs risk.
Theophylline (THEOCLEAR L. A.-130) is not associated with major teratogenic effects in humans. First trimester exposure does not increase risk of congenital malformations above baseline. Third trimester use may cause neonatal irritability, tachycardia, and vomiting due to transplacental transfer. Risk of fetal respiratory depression is low at therapeutic maternal levels.
SOMOPHYLLIN-CRT (theophylline) is a controlled-release formulation for chronic asthma/COPD. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active seizures. Use with caution in hepatic impairment, heart failure, and elderly. Cimetidine, fluoroquinolones, and macrolides increase levels; smoking and phenytoin decrease levels.
Theophylline has a narrow therapeutic index (10-20 mcg/m L). Levels >20 mcg/m L increase toxicity risk. Immunoassay cross-reactivity with caffeine and other xanthines may falsely elevate levels. Adjust dose in heart failure, liver disease, and for drug interactions with cimetidine, fluoroquinolones, and macrolides. Smoking induces metabolism requiring dose increase. Sustained-release formulations should not be crushed or chewed.
No interactions on record
No interactions on record
SOMOPHYLLIN-CRT and THEOCLEAR L.A.-130 are distinct pharmacological agents. SOMOPHYLLIN-CRT belongs to the Bronchodilator class and is primarily used for Treatment of asthma and chronic obstructive pulmonary disease (COPD)Apnea of prematurity (off-label)Facilitation of weaning from mechanical ventilation in neonates (off-label). THEOCLEAR L.A.-130 belongs to the Bronchodilator class and is primarily used for Treatment of asthma (FDA-approved)Treatment of chronic obstructive pulmonary disease (COPD) (off-label). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. SOMOPHYLLIN-CRT carries a safety status of Category C, whereas THEOCLEAR L.A.-130 safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism is saturable, leading to nonlinear pharmacokinetics. Less than 15% excreted unchanged in urine.
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4 (major); also N-demethylation and oxidation. Exhibits non-linear pharmacokinetics.
Primarily hepatic metabolism (90%) via CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for ~10% in adults, with minor biliary/fecal elimination (<1%).
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
~40% bound to albumin (primarily); binding is concentration-independent.
Approximately 40% bound to plasma proteins, primarily albumin. Binding is reversible and independent of concentration within therapeutic range.
0.4-0.6 L/kg (slightly higher in infants); approximates total body water; distributes widely into tissues including breast milk and CNS.
Vd of 0.3-0.7 L/kg (average 0.5 L/kg) approximates total body water. This indicates extensive distribution into tissues, with higher concentrations in tissues than plasma.
Oral immediate-release: 80-100%; Oral sustained-release: 90-100% (with less fluctuation); Rectal: 75-90% (variable due to absorption).
Oral bioavailability of the sustained-release formulation approaches 100% due to complete absorption. However, food can affect absorption rate; with Theoclear L. A.-130, high-fat meals may increase peak concentration and rate of absorption.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor levels. Child-Pugh Class C: reduce dose by 75% or consider alternative; monitor levels closely.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels closely.
Children >1 year: initial dose 10-16 mg/kg/day orally q12h (extended-release). Titrate to serum theophylline levels of 5-15 mcg/m L. Maximum 400 mg/day or 16 mg/kg/day, whichever is less.
Not recommended for children under 6 years; for children 6-12 years: 130 mg once daily initially, titrate based on weight and serum levels (target 5-15 mcg/m L).
Elderly patients: start at lowest possible dose (e.g., 200-300 mg once daily) due to reduced clearance. Monitor serum theophylline levels closely; target lower end of therapeutic range (5-12 mcg/m L). Avoid use if possible due to increased risk of toxicity.
Initiate at lower end of dosing range (130 mg once daily) and titrate slowly; monitor for toxicity due to reduced clearance.
No FDA black box warning.
Avoid charcoal-broiled foods as they may decrease theophylline levels. High-fat meals can alter absorption; take consistently with regard to meals. Caffeine-containing foods and beverages should be limited due to additive stimulation.
Avoid high-fat meals which may alter absorption of sustained-release tablets. Limit caffeine intake from coffee, tea, cola, and chocolate. Charcoal-grilled foods may increase clearance. No specific dietary restrictions beyond caffeine moderation; maintain consistent diet to avoid fluctuations in drug levels.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Breastfeeding is generally considered compatible but may cause irritability or sleep disturbances in the infant. Monitor infant for signs of theophylline toxicity. Use lowest effective maternal dose.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.6-0.7. Infant exposure is about 1-10% of maternal weight-adjusted dose. Adverse effects in nursing infants (irritability, sleep disturbance) have been reported. Caution advised; monitor infant for toxicity.
During pregnancy, theophylline clearance may increase (especially in second and third trimesters), requiring dose adjustments. Monitor serum concentrations closely and increase dose as needed to maintain therapeutic levels. Clearance returns to non-pregnant levels postpartum.
Pregnancy decreases theophylline clearance (especially third trimester due to decreased hepatic metabolism) and increases volume of distribution. Dose requirements may decrease by 20-30% in later pregnancy. Monitor serum levels and adjust dose to maintain therapeutic range (5-15 mcg/m L). Postpartum clearance returns rapidly (within 2 weeks); dose reduction may be needed to avoid toxicity.
Swallow tablets whole; do not crush or chew.,Take at the same time each day with a full glass of water.,Avoid excessive caffeine (coffee, tea, cola, chocolate) to prevent increased stimulation.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Do not change brand or formulation without consulting your doctor.,Store at room temperature, away from moisture.
Do not crush or chew sustained-release tablets; swallow whole.,Take exactly as prescribed; do not double doses if missed.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, palpitations, or seizures.,Inform all healthcare providers you are taking this medication.,Do not stop suddenly without consulting your doctor.